10X Genomics Price To Sales vs. Shares Outstanding

TXG Stock  USD 15.99  0.17  1.07%   
Based on 10X Genomics' profitability indicators, 10X Genomics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess 10X Genomics' ability to earn profits and add value for shareholders.

10X Genomics Price To Sales Ratio

14.35

At this time, 10X Genomics' Sales General And Administrative To Revenue is most likely to slightly decrease in the upcoming years. The 10X Genomics' current Price Sales Ratio is estimated to increase to 14.35, while Operating Cash Flow Sales Ratio is projected to decrease to (0.03). At this time, 10X Genomics' Non Operating Income Net Other is most likely to increase significantly in the upcoming years. The 10X Genomics' current Total Other Income Expense Net is estimated to increase to about 17.4 M, while Operating Income is forecasted to increase to (252.1 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.860.6615
Significantly Up
Slightly volatile
For 10X Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of 10X Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well 10X Genomics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between 10X Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of 10X Genomics over time as well as its relative position and ranking within its peers.
  

10X Genomics' Revenue Breakdown by Earning Segment

Check out World Market Map.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
5.261
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.11)
Return On Equity
(0.25)
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

10X Genomics Shares Outstanding vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining 10X Genomics's current stock value. Our valuation model uses many indicators to compare 10X Genomics value to that of its competitors to determine the firm's financial worth.
10X Genomics is rated below average in price to sales category among its peers. It is rated third in shares outstanding category among its peers creating about  35,185,136  of Shares Outstanding per Price To Sales. At this time, 10X Genomics' Price To Sales Ratio is most likely to increase in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value 10X Genomics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

10X Shares Outstanding vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

10X Genomics

P/S

 = 

MV Per Share

Revenue Per Share

 = 
3.04 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

10X Genomics

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
107 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

10X Shares Outstanding Comparison

10X Genomics is currently under evaluation in shares outstanding category among its peers.

10X Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in 10X Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, 10X Genomics will eventually generate negative long term returns. The profitability progress is the general direction of 10X Genomics' change in net profit over the period of time. It can combine multiple indicators of 10X Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-429 K-450.4 K
Net Interest Income16.9 M17.7 M
Interest Income16.9 M17.8 M
Operating Income-265.3 M-252.1 M
Net Loss-255.1 M-267.9 M
Income Before Tax-248.8 M-261.2 M
Non Operating Income Net Other7.4 M7.8 M
Total Other Income Expense Net16.6 M17.4 M
Net Loss-149.4 M-156.9 M
Net Loss-255.1 M-267.9 M
Income Tax Expense6.3 M3.7 M
Change To Netincome158.6 M111.7 M
Net Loss(2.18)(2.29)
Income Quality 0.06  0.06 
Net Income Per E B T 1.03  0.82 

10X Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on 10X Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of 10X Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the 10X Genomics' important profitability drivers and their relationship over time.

Use 10X Genomics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if 10X Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 10X Genomics will appreciate offsetting losses from the drop in the long position's value.

10X Genomics Pair Trading

10X Genomics Pair Trading Analysis

The ability to find closely correlated positions to 10X Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace 10X Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back 10X Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling 10X Genomics to buy it.
The correlation of 10X Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as 10X Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if 10X Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for 10X Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your 10X Genomics position

In addition to having 10X Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:
Check out World Market Map.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
To fully project 10X Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of 10X Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include 10X Genomics' income statement, its balance sheet, and the statement of cash flows.
Potential 10X Genomics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although 10X Genomics investors may work on each financial statement separately, they are all related. The changes in 10X Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on 10X Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.